Nov 14, 2018
”During the quarter we proudly reported that Kristianstad Central Hospital in Sweden evaluated the CADScor®System with a positive outcome. Due to the good result the hospital´s clinical management team has now included the CADScor®System as method of ruling out CAD into the local procedures and the hospital will start using the system clinically during the fourth quarter.”
Extract from interim CEO Christian Lindholm's commentary to the Interim Report.
Third quarter (July-September) 2018 compared with same period 2017
First nine months (January–September) 2018 compared with same period 2017
Events before September 30, 2018
Events after September 30, 2018
For further information, please contact:
Christian Lindholm, CFO, email@example.com
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, firstname.lastname@example.org) is Certified Advisor of Acarix.